ASH 2023 preview – small-molecule duels
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
Bridge mirrors Black Diamond and Blueprint’s search for something better
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
ASCO 2023 – China’s Dizal claims broad coverage with a super-Tagrisso
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
